1.045
Xortx Therapeutics Inc stock is traded at $1.045, with a volume of 8,017.
It is up +3.47% in the last 24 hours and up +15.65% over the past month.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
See More
Previous Close:
$1.01
Open:
$0.9781
24h Volume:
8,017
Relative Volume:
0.15
Market Cap:
$4.02M
Revenue:
-
Net Income/Loss:
$-736.70K
P/E Ratio:
-104.50
EPS:
-0.01
Net Cash Flow:
$-4.14M
1W Performance:
-1.42%
1M Performance:
+15.65%
6M Performance:
-25.36%
1Y Performance:
-60.96%
Xortx Therapeutics Inc Stock (XRTX) Company Profile
Compare XRTX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
XRTX
Xortx Therapeutics Inc
|
1.045 | 4.02M | 0 | -736.70K | -4.14M | -0.01 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Xortx Therapeutics Inc Stock (XRTX) Latest News
XORTX Therapeutics Delays Yearly Report Filing - TipRanks
XORTX Therapeutics Higher in U.S. Pre-market Trading, Says FDA Type B Meeting Positive - marketscreener.com
XORTX Advances NDA Filing for Gout Treatment Following FDA Guidance - TipRanks
XORTX Therapeutics Provides Update On FDA Type B Meeting Request - marketscreener.com
XORTX Therapeutics Brief: Providing Update on FDA Type B Meeting Request - marketscreener.com
XORTX Provides Update on FDA Type B Meeting Request - GlobeNewswire
XORTX Therapeutics Inc. Provides Update on FDA Type B Meeting Request - marketscreener.com
XORTX Therapeutics Inc. Announces Grant of European Patent Supporting Gout and Autosomal Dominant Polycystic Kidney Disease Programs - marketscreener.com
XORTX Secures European Patent for Gout and Kidney Disease Therapies - TipRanks
XORTX Announces Grant of European Patent - GlobeNewswire
XORTX Secures Game-Changing European Patent for Gout and Kidney Disease Treatments - Stock Titan
XORTX Therapeutics receives Nasdaq notice for non-compliance - MSN
XORTX Therapeutics (XRTX) Faces Nasdaq Compliance Challenge - GuruFocus
XORTX Receives Nasdaq Notification for Minimum Bid Price Deficiency - MSN
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency - GlobeNewswire
XORTX Faces Nasdaq Price Compliance Challenge: 180 Days to Avoid Delisting Risk - Stock Titan
XORTX Therapeutics: Stocks Undervalued by Analyst Consensus on TSX-V (XRTX) - The Globe and Mail
1 Defense Stock to Buy for Protection During These Uncertain Times - The Globe and Mail
XORTX Therapeutics Releases Annual Information Form for 2024 - TipRanks
XORTX Therapeutics Faces Financial Challenges Amidst Operational Losses - TipRanks
XORTX Announces Update for Discussion with the FDA - GlobeNewswire
XORTX Therapeutics Announces Type B Meeting With FDA -March 19, 2025 at 07:56 am EDT - Marketscreener.com
XORTX Advances Gout Treatment Program with FDA Discussions - TipRanks
XORTX Therapeutics Brief: Announced Update for Discussion with the FDA -March 19, 2025 at 07:14 am EDT - Marketscreener.com
XORTX Announces Update For Discussion With The FDA -March 19, 2025 at 07:05 am EDT - Marketscreener.com
XORTX Advances Revolutionary Gout Treatment Toward FDA Review - StockTitan
Dr. Allen Davidoff, XORTX Therapeutics: Developing Novel Therapies for Progressive Kidney Disease - DocWire News
XORTX Starts Gout Program New Drug Application Talks With FDA -February 24, 2025 at 08:04 am EST - Marketscreener.com
XORTX Advances Gout Treatment Program with FDA Meeting Request - TipRanks
XORTX Commences Gout Program NDA Discussions with the FDA - GlobeNewswire
Can This New Gout Treatment Reach FDA Approval? XORTX Reveals Critical Timeline - StockTitan
XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial - br.ADVFN.com
XORTX to Present at Microcap Conference - GlobeNewswire
XORTX Therapeutics Engages Investors at Microcap Conference - TipRanks
Revolutionary Gout Treatment Developer XORTX Reveals Game-Changing Pipeline Updates - StockTitan
XRTXXortx Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
XORTX Therapeutics Announces Auditor Transition - MSN
XORTX Announces Change of Auditor - TipRanks
XORTX Therapeutics Appoints New Auditor to Enhance Financial Oversight - TipRanks
XORTX Therapeutics Announces Auditor Change to Davidson & Company LLP - StockTitan
XORTX Therapeutics Inc (NASDAQ:XRTX) Plunging -39.23% In 6 Months – Here’s What To Expect - Marketing Sentinel
Now Is The Time To Build A Position In XORTX Therapeutics Inc (NASDAQ:XRTX) - Marketing Sentinel
XORTX Therapeutics Expands Pipeline with Late-Stage Gout Program - TipRanks
XORTX Adds Late Stage Gout Program to Pipeline - GlobeNewswire
XORTX Launches XRx-026 Program for Allopurinol-Intolerant Gout Patients, Targets FDA Approval - StockTitan
Xortx Therapeutics Inc Stock (XRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):